Switching from cinacalcet to ebocalcet in secondary hyperparathyroidism patients during hemodialysis.
Phase 4
- Conditions
- Secondary hyperparathyroidism
- Registration Number
- JPRN-UMIN000036862
- Lead Sponsor
- Fujita Memorial Hospita, Department of Internal Medicine
- Brief Summary
After changing from cinacalcet to evocalcet, there was no change in parathyroid hormone around 11 months. There were no serious adverse events during the study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with malignant tumors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method oninferiority of ebocalcet to cinacalcet on serum parathyroid hormone suppression after 12 months
- Secondary Outcome Measures
Name Time Method Evaluation of safety of ebocalcet, especially including hypocalcemia